“I have known Drew For many years, we went to school, college and university together. As a scientist Drew possesses remarkable analytical and clinical skills, he is capable of thinking with a clear head, and come up with sound solutions to tackle the toughest of problems. Drew Is highly intelligent and excels from other people i have known due to his wealth of technical abilities and knowledge which he has built up over his academic and working career. He is hardworking, genuine and wouldn't mind going the extra mile to help others. I consider Drew a strong ally and a good friend, and a real asset to anyone whom he works for. I cannot recommend Drew enough for any future positions.”
Drew Ellershaw, DClinSci FRCPath
London, England, United Kingdom
356 followers
350 connections
About
Registered Clinical Scientist with Fellowship of the Royal College of Pathologists and…
Activity
-
It’s been 10yrs since we gathered to sign the 100,000 genomes agreement at 10 Downing Street! Such a privilege to lead the talented team at Illumina…
It’s been 10yrs since we gathered to sign the 100,000 genomes agreement at 10 Downing Street! Such a privilege to lead the talented team at Illumina…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Our latest study published in Genetics in Medicine showing the importance of BRIP1 pathogenic variants in Ovarian cancer with some thoughts on Lynch…
Our latest study published in Genetics in Medicine showing the importance of BRIP1 pathogenic variants in Ovarian cancer with some thoughts on Lynch…
Liked by Drew Ellershaw, DClinSci FRCPath
Experience
Education
Publications
-
Cell-Free DNA in Pediatric Solid Organ Transplantation Using a New Detection Method of Separating Donor-Derived from Recipient Cell-Free DNA
Clinical Chemistry
Abstract
Background
The use of cell-free DNA (cfDNA) as a noninvasive biomarker to detect allograft damage is expanding rapidly. However, quantifying the low fraction of donor-derived cfDNA (ddcfDNA) is challenging and requires a highly sensitive technique. ddcfDNA detection through unique donor single nucleotide polymorphisms (SNPs) is a recent new approach, however there are limited data in pediatric solid organ transplant (SOT) recipients.
Methods
We developed an assay using…Abstract
Background
The use of cell-free DNA (cfDNA) as a noninvasive biomarker to detect allograft damage is expanding rapidly. However, quantifying the low fraction of donor-derived cfDNA (ddcfDNA) is challenging and requires a highly sensitive technique. ddcfDNA detection through unique donor single nucleotide polymorphisms (SNPs) is a recent new approach, however there are limited data in pediatric solid organ transplant (SOT) recipients.
Methods
We developed an assay using a combination of 61 SNPs to quantify the ddcfDNA accurately using a custom R script to model for both the patient and donor genotypes requiring only a single sample from the allograft recipient. Performance of the assay was validated using genomic DNA (gDNA), cfDNA and donor samples where available.
Results
The R “genotype-free” method gave results comparable to when using the known donor genotype. applicable to both related and unrelated pairs and can reliably measure ddcfDNA (limit of blank, below 0.12%; limit of detection, above 0.25%; limit of quantification 0.5% resulting in 84% accuracy). 159 pediatric SOT recipients (kidney, heart, and lung) were tested without the need for donor genotyping. Serial sampling was obtained from 82 patients.
Conclusion
We have developed and validated a new assay to measure the fraction of ddcfDNA in the plasma of pediatric SOT recipients. Our method can be applicable in any donor-recipient pair without the need for donor genotyping and can provide results in 48 h at a low cost. Additional prospective studies are required to demonstrate its clinical validity in a large cohort of pediatric SOT recipients. -
Cheaper and Faster Analysis of Donor-Derived Cell-Free DNA in Children after Heart and Lung Transplantation; Validation of a New Assay
The Journal of Heart and Lung Transplantation
Purpose
Donor-derived cell-free cell free DNA (ddcfDNA) is a noninvasive biomarker undergoing investigation in adult heart and lung allograft recipients. Elevated ddcfDNA levels have been correlated with active rejection, most robustly for antibody-mediated rejection (ABMR). However, complex methodology limits clinical implementation of this promising biomarker. There are no data in the paediatric population.
-
Contiguous gene deletion of TBX5 and TBX3: report of another case
Clinical dysmorphology
-
Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up
Blood, The Journal of the American Society of Hematology
-
Trisomy 21 mid-trimester amniotic fluid induced pluripotent stem cells maintain genetic signatures during reprogramming: implications for disease modeling and cryobanking
Cellular Reprogramming (Formerly" Cloning and Stem Cells")
Languages
-
English
Native or bilingual proficiency
-
Mandarin Chinese
Limited working proficiency
-
Japanese
Elementary proficiency
Recommendations received
1 person has recommended Drew
Join now to viewMore activity by Drew
-
Each Wednesday when I drive to our #Cambridge office, I always wanted to stop by to take a photo of our fantastic site (you know I love #traveling…
Each Wednesday when I drive to our #Cambridge office, I always wanted to stop by to take a photo of our fantastic site (you know I love #traveling…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Connecticut Joins Movement to Provide Rapid Whole Genome Sequencing for Critically Ill Newborns! Connecticut has become the 13th state to offer…
Connecticut Joins Movement to Provide Rapid Whole Genome Sequencing for Critically Ill Newborns! Connecticut has become the 13th state to offer…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Really exciting to see research today carried out via the NHS Genomic Medicine Service that showed whole genome sequencing can improve the care of…
Really exciting to see research today carried out via the NHS Genomic Medicine Service that showed whole genome sequencing can improve the care of…
Liked by Drew Ellershaw, DClinSci FRCPath
-
The good news keeps coming! iHope Genetic Health has partnered with the New York Genome Center to provide no-cost genome sequencing to underserved…
The good news keeps coming! iHope Genetic Health has partnered with the New York Genome Center to provide no-cost genome sequencing to underserved…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Yesterday marked the last day of the school year and also the completion of my first year of teaching. I can hardly believe how quickly the time has…
Yesterday marked the last day of the school year and also the completion of my first year of teaching. I can hardly believe how quickly the time has…
Liked by Drew Ellershaw, DClinSci FRCPath
-
📊 New XLEAP-SBS performance data on Illumina's NextSeq 1000/2000 just released! See higher accuracy and faster run times compared to standard SBS…
📊 New XLEAP-SBS performance data on Illumina's NextSeq 1000/2000 just released! See higher accuracy and faster run times compared to standard SBS…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Camilla Colombo at Illumina is #hiring - Lead / Staff Bioinformatics Scientist to join her team in Cambridge, where you'll be working alongside…
Camilla Colombo at Illumina is #hiring - Lead / Staff Bioinformatics Scientist to join her team in Cambridge, where you'll be working alongside…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Feeling very grateful not only to work for a company that truly values these initiatives but also to work with the best team in the world 🌍
Feeling very grateful not only to work for a company that truly values these initiatives but also to work with the best team in the world 🌍
Liked by Drew Ellershaw, DClinSci FRCPath
-
Fantastic 2 days training at Illumina in Cambridge and also a great learning experience for 2 of my amazing staff. Now just need to demultiplex my…
Fantastic 2 days training at Illumina in Cambridge and also a great learning experience for 2 of my amazing staff. Now just need to demultiplex my…
Liked by Drew Ellershaw, DClinSci FRCPath
-
So i did a thing (extra-curricular). I published my first book called ‘How to Talk to Kids about Food; A Parent’s Handbook.’ The book combines my…
So i did a thing (extra-curricular). I published my first book called ‘How to Talk to Kids about Food; A Parent’s Handbook.’ The book combines my…
Liked by Drew Ellershaw, DClinSci FRCPath
-
The ACMG - American College of Medical Genetics and Genomics recommends Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) as first-tier…
The ACMG - American College of Medical Genetics and Genomics recommends Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) as first-tier…
Liked by Drew Ellershaw, DClinSci FRCPath
-
Have you seen the latest jobs at Illumina. We have a number of opportunities from; - Bioinformatics Scientists - Field Service Engineers - Marketing…
Have you seen the latest jobs at Illumina. We have a number of opportunities from; - Bioinformatics Scientists - Field Service Engineers - Marketing…
Liked by Drew Ellershaw, DClinSci FRCPath
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More